Zhong Lai

机构：Merck & Co., Inc., Rahway, NJ, USA (United States)

发表论文 48 篇 · 总被引 719 次 · h-index 13

代表论文

• Characterization of the Antigenic Heterogeneity of Lipoarabinomannan, the Major Surface Glycolipid of Mycobacterium tuberculosis , and Complexity of Antibody Specificities toward This Antigen (2018 · The Journal of Immunology · 被引 74)
• Discovery of a Potent and Selective DGAT1 Inhibitor with a Piperidinyl-oxy-cyclohexanecarboxylic Acid Moiety (2014 · ACS Medicinal Chemistry Letters · 被引 26)
• Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes (2015 · ACS Medicinal Chemistry Letters · 被引 23)
• Characterization of Structural Features and Diversity of Variable-Region Determinants of Related Quaternary Epitopes Recognized by Human and Rhesus Macaque Monoclonal Antibodies Possessing Unusually Potent Neutralizing Activities (2011 · Journal of Virology · 被引 20)
• The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes (2012 · ACS Medicinal Chemistry Letters · 被引 18)
• Investigation of Cardiovascular Effects of Tetrahydro-β-carboline sstr3 antagonists (2014 · ACS Medicinal Chemistry Letters · 被引 13)